On November 1, 2023 Genome Insight, a precision healthcare solutions company promoting whole-genome technology for accurate diagnosis and personalized treatment for cancer and rare disease, reported that it has closed a $23 million in a Series B-2 investment in its latest funding round (Press release, Genome Insight, NOV 1, 2023, View Source [SID1234636682]). The round was joined by Samsung Venture Investment Corporation, Asan Foundation, SCL Group, and Ignite Innovation. Existing investors participated in this round. This round follows a Series B investment in 2022 that also raised $23 million.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This investment will support Genome Insight’s pursuit of bringing whole-genome based precision diagnostics to routine clinical care. Earlier this year, the company announced the launch of CancerVision, a test that utilizes whole genome sequencing to offer precise, timely, and medical relevant information that assists in making individualized healthcare decision in cancer. CancerVision integrates advanced bioinformatics and computational techniques to determine whole-genome mutational profiles of individual cancer patients. The information is analyzed and curated for physicians in an easy-to-use format that captures the most relevant and actionable insights for each patient.
"Genomic data has the potential to unlock a new era in healthcare. We envision a future where genomic information is integral to standard patient care," says Young Seok Ju, the Founder and CEO at Genome Insight.
About CancerVision
CancerVision was designed to empower healthcare providers with the information necessary to make informed decisions tailored to an individual’s unique genomic profile. Whole genome sequencing (WGS) provides a more complete view (>99%) of a cancer’s genetic make-up than any other test currently available, including targeted panels and whole exome testing. CancerVision can provide detailed information about genomic mutations and other biomarkers that may be driving a patient’s cancer. This information can support healthcare providers in identifying potential treatment approaches, such as targeted therapies and clinical trials, tailored to an individual’s specific cancer type and genetic makeup.